Can low EPA, high omega-6 intake, FADS variation, and inflammation raise the arachidonic acid-to-EPA ratio?

The clinical and biochemical systems governing inflammation resolution rely on a delicate balance of fatty acid substrates, enzymatic conversion, and genetic influences. A convergence of dietary habits, genetic variations, and inflammatory processes can significantly alter this balance.

Dietary and genetic drivers of the AA:EPA ratio

The ratio of arachidonic acid (AA) to eicosapentaenoic acid (EPA) is highly sensitive to dietary substrate availability and enzymatic efficiency:

• Enzyme competition: Omega-6 and omega-3 pathways utilize the same rate-limiting enzymes—specifically delta-6 desaturase (encoded by FADS2) and delta-5 desaturase (encoded by FADS1). High availability of the omega-6 precursor, linoleic acid, competitively inhibits the desaturation of omega-3 precursors into EPA, shifting pathway flux toward AA production.
• FADS genetic variation: Polymorphisms in the FADS1/FADS2 gene cluster act as major regulators. "High-activity" FADS haplotypes accelerate the conversion of dietary omega-6 precursors into AA, elevating the AA:EPA ratio. Conversely, "low-activity" variants restrict biosynthesis of both fatty acids, leaving individuals highly dependent on preformed dietary marine EPA to normalize this ratio.
• Inflammatory mobilization: Systemic inflammatory activation triggers phospholipase enzymes (such as PLA2) that selectively cleave and mobilize AA from cell membrane phospholipids, accelerating fatty acid turnover and skewing circulating and membrane ratios further toward AA.

Reduction of pro-resolving mediator capacity

An elevated AA:EPA ratio directly compromises the body’s ability to resolve inflammation:

• Substrate starvation: EPA is the obligate substrate for E-series resolvins (RvE1–RvE4), which are critical specialized pro-resolving mediators (SPMs). Inadequate EPA directly starves the cyclooxygenase-2 (COX-2), cytochrome P450, and 5-lipoxygenase (5-LOX) pathways, restricting SPM synthesis.
• Enzyme competition: Because COX and LOX enzymes are shared between pathways, an elevated AA:EPA ratio tilts the competitive balance. An abundance of AA outcompetes EPA for these enzymes, directing lipid mediator synthesis away from E-series resolvins and toward classic pro-inflammatory eicosanoids.
• Inflammatory disruption: Chronic inflammatory states dysregulate the expression and activity of key lipoxygenases (such as 5-LOX and 15-LOX), disrupting the physiological "class switching" from pro-inflammatory to pro-resolving mediators and locking the system into a state of diminished SPM capacity.

Bottom line

Low EPA availability directly limits E-series resolvin synthesis, while high omega-6 intake, high-activity FADS desaturase variants, and active inflammatory states work in tandem to elevate the AA:EPA ratio, competitively suppressing the enzymatic synthesis of critical specialized pro-resolving mediators.